Nature of change: Appointment of Independent Director approved by shareholders at the 28th Annual General Meeting
Name and DIN: Ms. Jill Mary De Simone (DIN: 11483134)
Effective date and tenure: Appointment effective from January 22, 2026, for a term of 3 years until January 21, 2029 (both days inclusive)
Profile and qualifications: Accomplished biopharmaceutical executive and board director with extensive experience in driving growth, innovation, and governance across global healthcare organizations. Former President of U.S. Oncology at Merck. Career spans leadership roles at Merck, Teva, and Bristol Myers Squibb with full P&L responsibilities. Experience includes launching transformative therapies in oncology, HIV, women's health, and general medicine. Currently advises preclinical and early-stage companies on commercialization and leadership transitions. Serves on boards of public and private life sciences companies. Chairs advisory boards focused on AI in healthcare. Known for strategic acumen, authentic leadership, and commitment to purpose-driven cultures.
Eligibility confirmation: Not debarred from holding the office of Director by virtue of any SEBI or other authority order
Relationship with other directors: Not related to any Director of the Company
Approval mechanism: Appointment approved by shareholders at the 28th Annual General Meeting held on Thursday, August 13, 2026, through video conferencing/other audiovisual means
